Shots:
- The US FDA has approved an sBLA for Leqembi Iqlik (lecanemab‑irmb, SC) as an initiation dose administered as 500mg given QW as two 250mg injections, each delivered in ~15secs for the treatment of early Alzheimer’s disease
- Approval was supported by clinical data across multiple studies, with Clarity AD LTE sub-studies showing QW SC Leqembi achieved exposure comparable to IV dosing, supporting similar efficacy and amyloid removal
- Leqembi Iqlik for initiation dosing is expected to launch in the US in late Aug 2026. Eisai leads global development & regulatory submissions, co-commercializes the product with Biogen, and retains final decision-making authority
Ref: Eisai | Image: Eisai & Biogen | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
